Study evaluating safety, tolerability and clinical activity of GSK2857916 in combination with pembrolizumab in subjects with relapsed/refractory multiple myeloma (RRMM)

Trial Identifier: 205207
Sponsor: GlaxoSmithKline
Collaborator:
Merck
Start Date: March 2019
Primary Completion Date: October 2021
Study Completion Date: June 2023
Condition: Myeloma

Available Languages

For questions about your Trial Results Summary, please see Sponsor contact section within your Trial Results Summary.

Language Description

Trial Locations

Country Location
Canada, Alberta Calgary, Alberta, Canada, T2N 2T9
Canada, Ontario Toronto, Ontario, Canada, M5G 2M9
Germany, Berlin Berlin, Germany, 12200
Germany, Hamburg Hamburg, Germany, 20246
Germany, Niedersachsen Hannover, Niedersachsen, Germany, 30625
Spain Badalona, Spain, 08916
Spain Pozuelo de Alarcón/Madrid, Spain, 28223
Spain Salamanca, Spain, 37007
United States, Georgia Atlanta, Georgia, United States, 30322
United States, Indiana Indianapolis, Indiana, United States, 46202
United States, North Carolina Charlotte, North Carolina, United States, 28204
United States, Wisconsin Madison, Wisconsin, United States, 53792